Pharmaceuticals
Clinical trials of pharmaceutical products represent the single most expensive and time consuming component of the drug development process. A paper-based and detail orientated operation may involve thousands of pages of records that pass back and forth between and among the review board and the trial sponsor. The ability to accelerate the clinical trial process can result in huge cost savings that can be redirected to other significant R&D initiatives.
In order to protect this data while streamlining operations, Pharmaceutical companies are looking to move to secure email for trusted, fast communication. Many are turning to Voltage to provide a secure email communication channel that's easy to use and manage, meets government regulations (e.g. HIPAA and FDA 21 CFR Part 11), includes digital signatures, and is ubiquitous for study sites and their trial sponsors. Email is an efficient communications mechanism that is widely accepted throughout the industry. The stability and reliability of email is comforting to an industry entrenched in their ways.
By utilizing Voltage's Secure Messaging platform Pharmaceutical companies are optimizing communication and finding:
- Enhanced relationship management within clinical trials eliminating costly delays
- Streamlined drug trial submissions
- Rapid and secure two-way communication between geographically distributed research laboratories and facilities
- Successful encryption of unclassified/classified data for transmission to and from BlackBerry devices
- Seamlessly works with other Public Key Infrastructure (PKI) systems
With growing competition and the periods of product exclusivity dwindling, it is becoming increasingly important for pharmaceutical companies to use secure email to quickly communicate highly sensitive information. Information regarding clinical trials, finance, and R&D needs to be exchanged promptly to accelerate industry processes and increase ROI, and Voltage is here to help.
| 
